EXHALATION DELIVERY SYSTEM FOR AND METHOD OF TREATING SINUS DISEASE
An exhalation delivery system for and method of treating a patient having sinus disease, comprising, following Draf 2 or Draf 3 surgery, administering a therapeutic agent including a corticosteroid to the patient, wherein the therapeutic agent is administered by an exhalation delivery device comprising a mouthpiece and a nosepiece, fitting the nosepiece to a first nostril of the patient, and the patient exhaling into the mouthpiece to create a fluid flow out of the nosepiece and into the first nostril during administration of the therapeutic agent to the patient.
1 . A method of treating a patient having a sinus condition, comprising, administering a therapeutic agent including a corticosteroid to the patient after the patient undergoes Draf 2 of Draf 3 surgery, wherein the therapeutic agent is administered via an exhalation delivery device that comprises a mouthpiece and a nosepiece, the nosepiece fitted to a first nostril of the patient, wherein the patient exhales into the mouthpiece to create a fluid flow out of the nosepiece and into the first nostril while the therapeutic agent is administered to the patient.
2 . The method of claim 1 , wherein the corticosteroid is fluticasone.
3 . The method of claim 1 , wherein the corticosteroid is fluticasone propionate.
4 . The method of claim 1 , wherein the surgery is Draf 2 surgery.
5 . The method of claim 1 , wherein the surgery is Draf 3 surgery.
6 . The method of claim 1 , wherein the therapeutic agent is in the form of a liquid aerosol.
7 . The method of claim 6 , wherein the therapeutic agent is administered using a spray pump.
8 . The method of claim 1 , wherein the therapeutic agent is in the form of a powder.
9 . The method of claim 1 , wherein the therapeutic agent is delivered in an amount of up to 400 μg.
10 . The method of claim 1 , wherein the therapeutic agent is delivered in an amount of up to 200 μg.
11 . The method of claim 1 , wherein the therapeutic agent is delivered in an amount of up to 100 μg.
12 . The method of claim 1 , wherein the therapeutic agent is delivered in an amount of at least 50 μg.
13 . The method of claim 1 , further comprising controlling a duration, rate or pressure of the fluid flow.
14 . The method of claim 13 , comprising controlling the fluid flow duration to be in a range of from about 2 seconds to about 3 seconds.
15 . The method of claim 13 , comprising controlling the fluid flow rate to be at least 10 Lmin −1 .
16 . The method of claim 1 , wherein the nosepiece is fitted to a second nostril of the patient, wherein the patient exhales into the mouthpiece to create a fluid flow out of the nosepiece and into the second nostril while the therapeutic agent is administered to the patient.
17 . The method of claim 16 , wherein the first and second nostrils are different nostrils of the patient or the same nostril of the patient.
18 . (canceled)
19 . The method of claim 18 , wherein the surgery is endoscopic sinus surgery.
20 . The method of claim 1 , wherein the sinus condition is chronic rhinosinusitis (CRS).
21 . The method of claim 9 , wherein the therapeutic agent is delivered twice daily.
22 . The method of claim 10 , wherein the therapeutic agent is delivered twice daily.
23 . The method of claim 11 , wherein the therapeutic agent is delivered twice daily.
24 . The method of claim 12 , wherein the therapeutic agent is delivered twice daily.